Clinical Trial

A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 24, 2024 (before its estimated July 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a 24 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase IIb trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesity, and to explore the optimal dose selection to support the subsequent Pivotal trial.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-18.
Trial Details
NCT Number NCT06606483
Lead Sponsor MindRank AI Ltd
Conditions Obesity, Overweight and Obesity
Enrollment 300 participants
Start Date 2024-09-23
Primary Completion 2025-07-30 (estimated)
Study Completion 2025-09-30 (estimated)
Updated on ClinicalTrials.gov 2024-09-24